Sarcoidosis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Xentria, Inc., aTyr Pharma, Inc., Pfizer, United Therapeutics

The Sarcoidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Sarcoidosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcoidosis Market.

Some of the key takeaways from the Sarcoidosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Sarcoidosis treatment therapies with a considerable amount of success over the years. 
• Sarcoidosis companies working in the treatment market are Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others, are developing therapies for the Sarcoidosis treatment 

• Emerging Sarcoidosis therapies in the different phases of clinical trials are- Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others are expected to have a significant impact on the Sarcoidosis market in the coming years.   
• In September 2022, aTyr Pharma, Inc. revealed the initiation of dosing for the initial patient in the worldwide pivotal EFZO-FIT™ trial. This Phase III study aims to assess the effectiveness and safety of the company’s primary therapeutic candidate, efzofitimod, in comparison to a placebo among individuals diagnosed with pulmonary sarcoidosis, a significant type of interstitial lung disease (ILD).
• In August 2022, The FDA has awarded Fast Track designation to efzofitimod (ATYR1923) for addressing pulmonary sarcoidosis. Additionally, efzofitimod has obtained FDA orphan drug designation specifically for the treatment of sarcoidosis.

Sarcoidosis Overview

The multisystem illness sarcoidosis, whose cause is uncertain, is typified by non-caseating granulomas in the organs. This disease primarily affects young individuals and is characterized by bilateral hilar lymphadenopathy and reticular opacities in the lungs.

Get a Free Sample PDF Report to know more about Sarcoidosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sarcoidosis-pipeline-insight

Emerging Sarcoidosis Drugs Under Different Phases of Clinical Development Include:

• Abrocitinib: Pfizer
• Inhaled Treprostinil: United Therapeutics
• XTMAB-16: Xentria, Inc.
• Efzofitimod: aTyr Pharma, Inc./Kyorin Pharmaceutical Co., Ltd
• CMK389: Novartis
• Namilumab: Kinevant Sciences GmbH
• FP-020: Foresee Pharmaceuticals
• LAM001: AI Therapeutics
• OATD-01: Molecure

Sarcoidosis Route of Administration

Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Sarcoidosis Molecule Type

Sarcoidosis Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Sarcoidosis Pipeline Therapeutics Assessment

• Sarcoidosis Assessment by Product Type
• Sarcoidosis By Stage and Product Type
• Sarcoidosis Assessment by Route of Administration
• Sarcoidosis By Stage and Route of Administration
• Sarcoidosis Assessment by Molecule Type
• Sarcoidosis by Stage and Molecule Type

DelveInsight’s Sarcoidosis Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sarcoidosis product details are provided in the report. Download the Sarcoidosis pipeline report to learn more about the emerging Sarcoidosis therapies

Some of the key companies in the Sarcoidosis Therapeutics Market include:

Key companies developing therapies for Sarcoidosis are – Xentria, Inc., aTyr Pharma, Inc., Pfizer, United Therapeutics, Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, and others.

Sarcoidosis Pipeline Analysis:

The Sarcoidosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
• Sarcoidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sarcoidosis drugs and therapies

Sarcoidosis Pipeline Market Drivers

• Strategic alliances between the Pharmaceutical companies and universities, extensive research undertaking and funding are some of the important factors that are fueling the Sarcoidosis Market.

Sarcoidosis Pipeline Market Barriers

• However, side-effects associated with the treatment of Sarcoidosis, lack of awareness among people in developing countries and other factors are creating obstacles in the Sarcoidosis Market growth.

Scope of Sarcoidosis Pipeline Drug Insight    

• Coverage: Global
• Key Sarcoidosis Companies: Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, aTyr Pharma, and others
• Key Sarcoidosis Therapies: Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others
• Sarcoidosis Therapeutic Assessment: Sarcoidosis current marketed and Sarcoidosis emerging therapies
• Sarcoidosis Market Dynamics: Sarcoidosis market drivers and Sarcoidosis market barriers 

Request for Sample PDF Report for Sarcoidosis Pipeline Assessment and clinical trials

Table of Contents

1. Sarcoidosis Report Introduction

2. Sarcoidosis Executive Summary

3. Sarcoidosis Overview

4. Sarcoidosis- Analytical Perspective In-depth Commercial Assessment

5. Sarcoidosis Pipeline Therapeutics

6. Sarcoidosis Late Stage Products (Phase II/III)

7. Sarcoidosis Mid Stage Products (Phase II)

8. Sarcoidosis Early Stage Products (Phase I)

9. Sarcoidosis Preclinical Stage Products

10. Sarcoidosis Therapeutics Assessment

11. Sarcoidosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sarcoidosis Key Companies

14. Sarcoidosis Key Products

15. Sarcoidosis Unmet Needs

16 . Sarcoidosis Market Drivers and Barriers

17. Sarcoidosis Future Perspectives and Conclusion

18. Sarcoidosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services